SLRX Salarius Pharmaceuticals Inc: Accounting Value per Share

Public company logo of Salarius Pharmaceuticals Inc (SLRX)

Salarius Pharmaceuticals (SLRX) is creating a closed-loop precision oncology environment through unique patented inhibitors. The growth rate of the stock's book value confirms this foundation, where the value of 4.50 captures the metric level. Robotic molecule discovery optimizes laboratory screenings, reducing headcount. Meanwhile, management is strictly limiting expenses, adapting the pipeline to partner expectations and preserving capital.

Salarius Pharmaceuticals Inc (SLRX) - Accounting Value per Share from 07/04/2022 to 01/08/2026
Manufactured product of salariuspharma.com

For Salarius Pharmaceuticals (SLRX), whose value is based on R&D capitalization and patents, this indicator reflects the difference between all assets and liabilities allocated per common share. This metric serves as an objective indicator of financial stability, allowing for a comparison between the actual value of net assets and market expectations, which the book value per common share price action clearly demonstrates.

Competitor analysis for Salarius Pharmaceuticals

Net Assets per Single Share BeiGene Corp (ONC)|Halozyme Corp (HALO) - Accounting Value of a Share|Accounting Value per Share Revolution Medicines|ascentage.com (AAPG) - Equity per Share|Book Value per Share CGON|Accounting Value per Share UroGen Pharma Ltd|Book Value per Share BCAX|Book Value per Share PSNL (Personalis Genomics)|ERAS - Net Assets per Single Share|Equity per Share delcath.com DCTH|YMAB: Book Value per Share|AURA - Accounting Value per Share|Book Value per Share CADL|ARAY (Accuray, Inc.) - Net Asset Value per Share|SLS - Net Assets per Single Share|Accounting Value of a Share actuatetherapeutics.com (ACTU)|Citius Oncology (CTOR) - Accounting Value per Share|Accounting Value of a Share tuhurabio.com (HURA)|Protara - Book Value per Share|FATE - Accounting Value per Share|Aadi Bio - Accounting Value per Share|TCRX: Book Value per Share|Net Assets per Single Share championsoncology.com CSBR|XBiotech (XBIT) - Accounting Value of a Share|Book Value per Share CVM (CEL-SCI Corp.)|Net Asset Value per Share OSTX|RADX (Radiopharm Theranostics Limited) - Net Assets per Single Share|Net Assets per Share artivabio.com (ARTV)|Book Value per Share ANL (Adlai Nortye)|Veru Inc - Book Value per Share|TPST - Net Assets per Single Share|XLO - Net Assets per Single Share|RENB: Book Value per Share|MURA (Mural Oncology) - Book Value per Share|KAPA - Net Assets per Single Share|Accounting Value of a Share OnKure|GDTC (CytoMed Therapeutics) - Book Value per Share|Net Assets per Share curis.com CRIS|Accounting Value per Share APLM (Apollomics)|tharimmune.com - Book Value per Share|Net Assets per Single Share ADVB (Advanced Biomed Corp)|Genprex Inc. (GNPX) - Net Assets per Share|Accounting Value per Share calidibio.com CLDI|SBFM (Sunshine Biopharma Inc.) - Accounting Value of a Share|Net Assets per Single Share Xenetic Biosciences Inc. XBIO|Share Book Value purple-biotech.com|American Oncology Network (AONC) - Book Value per Share|Accounting Value of a Share BeiGene Ltd. (BGNE)|Book Value per Share CKPT (Checkpoint Therapeutics, Inc)|elevationoncology.com - Book Value per Share|Net Assets per Single Share iCAD Corp (ICAD)|IKNA: Accounting Value of a Share|NTBL (Notable Labs) - Net Assets per Single Share|Viracta Therapeutics, Inc. (VIRX) - Accounting Value per Share|MOR (MorphoSys Corp) - Book Value per Share|Book Value per Share NAYA Biosciences Corp|Book Value per Share AAPGV (Ascentage Pharma Group)